CVS Health (NYSE:CVS – Get Rating) had its target price boosted by Morgan Stanley from $119.00 to $120.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the pharmacy operator’s stock. Morgan Stanley’s target price would indicate a potential upside of 32.96% from the company’s previous close.
Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. decreased their target price on shares of CVS Health from $130.00 to $125.00 and set an “overweight” rating for the company in a research report on Thursday, November 3rd. Wells Fargo & Company decreased their price target on CVS Health from $106.00 to $101.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 3rd. TheStreet raised shares of CVS Health from a “c+” rating to a “b” rating in a report on Friday, November 25th. The Goldman Sachs Group lowered their target price on shares of CVS Health from $128.00 to $113.00 and set a “buy” rating on the stock in a research note on Thursday, November 3rd. Finally, Bank of America decreased their price objective on shares of CVS Health from $122.00 to $118.00 and set a “buy” rating for the company in a report on Thursday, October 20th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.13.
CVS Health Stock Performance
Shares of NYSE:CVS traded up $1.07 during trading on Friday, hitting $90.25. 169,592 shares of the company traded hands, compared to its average volume of 9,149,684. The stock has a market capitalization of $118.59 billion, a price-to-earnings ratio of 38.40, a PEG ratio of 1.41 and a beta of 0.71. CVS Health has a one year low of $86.28 and a one year high of $111.25. The company has a quick ratio of 0.69, a current ratio of 0.94 and a debt-to-equity ratio of 0.72. The business’s fifty day moving average is $97.11 and its 200-day moving average is $97.19.
CVS Health (NYSE:CVS – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The pharmacy operator reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.10. CVS Health had a return on equity of 15.56% and a net margin of 1.00%. The firm had revenue of $81.16 billion during the quarter, compared to the consensus estimate of $76.53 billion. As a group, equities analysts predict that CVS Health will post 8.65 earnings per share for the current fiscal year.
Insider Transactions at CVS Health
In other CVS Health news, EVP Thomas M. Moriarty sold 137,466 shares of CVS Health stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $98.36, for a total transaction of $13,521,155.76. Following the completion of the sale, the executive vice president now owns 608,129 shares of the company’s stock, valued at approximately $59,815,568.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is owned by insiders.
Institutional Investors Weigh In On CVS Health
A number of hedge funds and other institutional investors have recently made changes to their positions in CVS. BRYN MAWR TRUST Co raised its holdings in shares of CVS Health by 1.5% during the 2nd quarter. BRYN MAWR TRUST Co now owns 6,459 shares of the pharmacy operator’s stock valued at $598,000 after purchasing an additional 98 shares in the last quarter. Cobblestone Capital Advisors LLC NY boosted its stake in shares of CVS Health by 3.3% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 3,136 shares of the pharmacy operator’s stock worth $299,000 after acquiring an additional 100 shares in the last quarter. Tortoise Investment Management LLC increased its holdings in shares of CVS Health by 6.3% during the 2nd quarter. Tortoise Investment Management LLC now owns 1,714 shares of the pharmacy operator’s stock valued at $159,000 after acquiring an additional 102 shares during the last quarter. IFG Advisors LLC raised its stake in shares of CVS Health by 4.0% in the 3rd quarter. IFG Advisors LLC now owns 2,667 shares of the pharmacy operator’s stock valued at $254,000 after acquiring an additional 102 shares in the last quarter. Finally, First National Trust Co boosted its position in CVS Health by 2.9% during the third quarter. First National Trust Co now owns 3,640 shares of the pharmacy operator’s stock worth $347,000 after purchasing an additional 104 shares during the period. 77.29% of the stock is owned by hedge funds and other institutional investors.
About CVS Health
CVS Health Corporation provides health services in the United States. The company’s Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVS Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CVS Health wasn’t on the list.
While CVS Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
